HomePertuzumab Trastuzumab And Hyaluronidase ZzxfPertuzumab Trastuzumab And Hyaluronidase Zzxf + Anthracycline

Does Pertuzumab Trastuzumab And Hyaluronidase Zzxf Interact with Anthracycline?

Pertuzumab Trastuzumab And Hyaluronidase Zzxf and Anthracycline have a major drug interaction according to U.S. FDA drug labeling data. 7 DRUG INTERACTIONS Patients who receive anthracycline after stopping PHESGO may be at increased risk of cardiac dysfunction because of PHESGO's long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping PHESGO. If anthracyclines are used, carefully monitor the patient's cardiac function. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Pertuzumab Trastuzumab And Hyaluronidase Zzxf Class
HER2/neu Receptor Antagonist
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Pertuzumab Trastuzumab And Hyaluronidase Zzxf and your doctor is considering prescribing Anthracycline (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Pertuzumab Trastuzumab And Hyaluronidase Zzxf(Phesgo)+💊 Anthracycline

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
HER2/neu Receptor Antagonist
Drug B class
Source
FDA drug label - pertuzumab, trastuzumab, and hyaluronidase-zzxf

What this means in plain English

7 DRUG INTERACTIONS Patients who receive anthracycline after stopping PHESGO may be at increased risk of cardiac dysfunction because of PHESGO's long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping PHESGO. If anthracyclines are used, carefully monitor the patient's cardiac function.

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Pertuzumab Trastuzumab And Hyaluronidase Zzxf and Anthracycline against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.